Filtreler

2025 - 20262
Filtreleri Sıfırla

Ayarlar

İndeks: PubMed × Konu: Autism ×

Arama Sonuçları

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Yayın
    Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: a living systematic review with meta-analysis
    (Elsevier B.V., 2025-12) Højlund, Mikkel; Yılmaz Kafalı, Helin; Kırmızı, Begüm; Fusar-Poli, Paolo; Correll, Christoph U.; Cortese, Samuele; Sabé, Michel; Fiedorowicz, Jess; Saraf, Gayatri; Zein, Josephine; Berk, Michael; Husain, Muhammad I.; Rosenblat, Joshua D.; Rubaiyat, Ruby; Corace, Kim; Wong, Stanley; Hatcher, Simon; Kaluzienski, Mark; Yatham, Lakshmi N.; Cipriani, Andrea; Gosling, Corentin J.; Carhart-Harris, Robin; Tanuseputro, Peter; Myran, Daniel T.; Fabiano, Nicholas; Moher, David; Mayo, Leah M.; Nicholls, Stuart G.; White, Tracy; Prisco, Michele De; Radua, Joaquim; Vieta, Eduard; Ladha, Karim S.; Katz, Jay; Veroniki, Areti A.; Solmi, Marco
    Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in disease-specific symptoms and all-cause discontinuation. Standardized mean differences (SMD) and relative risk (RR) were estimated using random-effects meta-analysis. Risk of bias (RoB) was assessed with Cochrane’s RoB-tool version 2 and certainty of evidence with GRADE. The review is maintained as living systematic review ( https://ebipsyche-database.org/ ). We included 30 RCTs (1480 participants; female=45.8 %; with psychological support=83.3 %; high RoB=83.3 %). In post-traumatic stress disorder (PTSD), MDMA reduced PTSD symptoms compared to any control ( k = 11; SMD=-0.85 [-1.09; -0.60]; I2=0 %; GRADE=low). In major depressive disorder (MDD), psilocybin/ayahuasca/LSD reduced depressive symptoms ( k = 8; SMD=-0.62 [-0.97; -0.28]; I2=55 %; GRADE=very low). In anxiety disorders, both MDMA and serotonergic psychedelics reduced anxiety symptoms (SMDMDMA=-1.18 [-2.04; -0.32]; I2=0 %; k = 2; GRADE=low and SMDserotonergic=-0.88 [-1.70; -0.06]; I2=54 %; k = 5; GRADE=very low). In alcohol use disorder, neither psilocybin nor LSD reduced abstinence rates ( k = 6; RR=1.42 [0.89; 2.26]; I2=7 %; GRADE=very low). In attention-deficit hyperactivity disorder (ADHD), LSD did not reduce ADHD symptoms ( k = 1; SMD=0.22 [-0.32; 0.76]; GRADE=very low). Moderate certainty in evidence was only found for MDMA on PTSD symptoms when compared to placebo. MDMA/serotonergic psychedelics were not associated with higher risk of all-cause discontinuation (RRMDMA=0.74 [0.32; 1.72]; RRserotonergic=0.81 [0.56; 1.15]). Overall, MDMA/serotonergic psychedelics are promising for the treatment of PTSD, MDD, and anxiety disorders with moderate to large effect sizes. Pragmatic trials, long-term, head-to-head trials exploring the role of psychological support, aiming to identify predictors of response, and accounting for expectancy and functional unblinding are needed. Studies addressing these limitations will likely be required for regulatory approval of psychedelic drugs.
  • Küçük Resim
    Yayın
    Validation and normative data study for the Turkish version of the movie for the assessment of social cognition (MASC-TR)
    (Oxford University Press, 2026-02-05) Şandor, Serra; Hıdıroğlu-Ongun, Ceren; Tanfer, Mehmet Can; Gürkaş, Sena; Bora, Emre; Yıldırım, Elif
    Objective This study aimed to adapt the Movie for the Assessment of Social Cognition (MASC) into Turkish (MASC-TR), examine its psychometric properties, and establish normative data. Additionally, the study investigated the discriminative validity of the MASC-TR in differentiating individuals with autism spectrum disorder (ASD) from healthy controls. Methods The sample comprised 228 healthy adults and 29 individuals with ASD aged 18–45 years. Participants completed the MASC-TR along with established measures of theory of mind (ToM)—the Reading the Mind in the Eyes Test (RMET) and the Faux Pas Recognition Test (FPRT)—as well as non-social cognitive tasks assessing attention, working memory, and executive functions. Reliability analyses included internal consistency and test–retest reliability. Construct validity was assessed via convergent and discriminant correlations. Group comparisons and receiver operating characteristic analyses were used to evaluate discriminative validity, while multifactorial analysis of variance and regression analyses examined demographic effects. Results The MASC-TR demonstrated acceptable internal consistency (α=0.75) and excellent test–retest reliability (ICC=0.98). Significant positive correlations with RMET and FPRT supported convergent validity. Education level emerged as the only significant demographic predictor of MASC-TR performance. The MASC-TR successfully differentiated individuals with ASD from controls (t=−3.87, p<.001), with an optimal cutoff of 23.5 yielding 97% sensitivity and 52% specificity (area under the curve=0.72). Conclusions The findings indicate that the MASC-TR is a valid and reliable measure of social cognition in Turkish adults. The availability of culturally adapted normative data enhances its clinical and research utility for assessing ToM functioning across populations.